(Q36127815)

12 August 2017

Experimental Treatment of Ebola Virus Disease with Brincidofovir (English)

1 reference

12 August 2017

Ebola hemorrhagic fever

0 references

Orthoebolavirus zairense

0 references

1

Jake Dunning

0 references

Lyndsey Castle

object named as

Lyndsey Castle

8

0 references

Peter W. Horby

object named as

Peter W Horby

15

0 references

Gail Carson

6

object named as

Gail Carson

1 reference

12 August 2017

14

Piero Olliaro

1 reference

12 August 2017

13

Trudie Lang

1 reference

12 August 2017

Stephen B Kennedy

2

1 reference

12 August 2017

Annick Antierens

3

1 reference

12 August 2017

John Whitehead

4

1 reference

12 August 2017

Iza Ciglenecki

5

1 reference

12 August 2017

Rupa Kanapathipillai

7

1 reference

12 August 2017

Rebecca Howell-Jones

9

1 reference

12 August 2017

Raul Pardinaz-Solis

10

1 reference

12 August 2017

Jennifer Grove

11

1 reference

12 August 2017

Janet Scott

12

1 reference

12 August 2017

RAPIDE-BCV trial team

16

1 reference

12 August 2017

language of work or name

English

0 references

publication date

9 September 2016

1 reference

12 August 2017

1 reference

12 August 2017

11

1 reference

12 August 2017

9

1 reference

12 August 2017

e0162199

1 reference

Creative Commons Attribution 4.0 International

12 August 2017

start time

9 September 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5017617

The Contribution of Ebola Viral Load at Admission and Other Patient Characteristics to Mortality in a Médecins Sans Frontières Ebola Case Management Centre, Kailahun, Sierra Leone, June-October 2014

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5017617

Clinical Features of Patients With Ebola Virus Disease in Sierra Leone

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5017617

High survival rates and associated factors among ebola virus disease patients hospitalized at donka national hospital, conakry, Guinea

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5017617

Administration of Brincidofovir and Convalescent Plasma in a Patient With Ebola Virus Disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5017617

Characteristics and Clinical Management of a Cluster of 3 Patients With Ebola Virus Disease, Including the First Domestically Acquired Cases in the United States

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5017617

The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5017617

Evaluating clinical trial designs for investigational treatments of Ebola virus disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5017617

Clinical predictors of mortality in patients with Ebola virus disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5017617

The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: a model of smallpox disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5017617

Clinical care of two patients with Ebola virus disease in the United States

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5017617

Ebola virus disease in West Africa--clinical manifestations and management

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5017617

Clinical presentation of patients with Ebola virus disease in Conakry, Guinea

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5017617

Clinical illness and outcomes in patients with Ebola in Sierra Leone

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5017617

First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5017617

Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5017617

Development of CMX001 for the Treatment of Poxvirus Infections

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5017617

Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5017617

CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5017617

Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5017617

10.1371/JOURNAL.PONE.0162199

23 September 2018

Identifiers

DOI

1 reference

12 August 2017

0 references

1 reference

12 August 2017

1 reference